VABYSMO (faricimab) Clinical, Regulatory and Commercial Intelligence Report 2026
VABYSMO (faricimab), developed by Genentech/Roche, has become a multibillion-dollar blockbuster ophthalmology drug with global sales reaching CHF 3.9 billion in 2024 (68% YoY growth). The bispecific monoclonal antibody targeting VEGF-A and Ang-2 is approved for neovascular AMD, diabetic macular edema, and retinal vein occlusion, with recent clinical data supporting efficacy in polypoidal choroidal vasculopathy. Market expansion opportunities include geographic growth, new indications in diabetic retinopathy and choroidal neovascularization, and competitive advantages over VEGF-only therapies through extended dosing intervals.